Large-Volume Liver Metastases from Neuroendocrine Tumors: Hepatic Intraarterial90Y-DOTA-Lanreotide as Effective Palliative Therapy
Authors:
- Dave MaudgilDMDave Maudgil
- Martin WilliamsMWMartin Williams
- Jonathan M. TibballsJTJonathan M. Tibballs
- Anthony F. WatkinsonAWAnthony F. Watkinson
- Martyn E. CaplinMCMartyn E. Caplin
- John R. BuscombeJBJohn R. Buscombe
- 1 November 2005
- journal article
- Published by Radiological Society of North America (RSNA) in Radiology
- Vol. 237 (2) , 718-726
Abstract
To prospectively evaluate the safety and effectiveness of hepatic intraarterial injection of yttrium 90 ((90)Y) tetraazacyclododecane tetraacetic acid (DOTA) lanreotide as a treatment for patients with progressive large-volume somatostatin receptor-positive liver metastases from neuroendocrine tumors. The study was local ethics committee approved, and all patients gave informed consent. Twenty-three patients (13 men, 10 women; age range, 21-69 years; median age, 57 years) with histologically proved large-volume liver metastases from neuroendocrine cancers were treated. All patients had radiologic evidence of liver disease progression and high uptake of indium 111 ((111)In) pentetreotide at scintigraphy. Selective hepatic intraarterial injection of (90)Y-DOTA-lanreotide (total of 36 treatments; median activity per dose, 1 GBq) was administered with or without embolization. Treatment cycles were performed in 8-week intervals. Clinical, biologic, and radiologic tumor responses were assessed 8-12 weeks after each treatment cycle. Objective tumor response was classified according to World Health Organization response criteria as complete regression, partial response, stable disease, or disease progression. Kaplan-Meier survival curves were used to calculate 1-year survivals. Partial response to treatment was achieved in three (16%) of 19 patients, and stable disease was achieved in 12 (63%). Four (21%) of 19 patients had continued disease progression. Clinical improvement was reported by 14 (61%) of the 23 patients, and a reduction in biologic marker levels was observed in nine (60%) of 15 patients. Reversible hematologic toxicity (National Cancer Institute common toxicity criteria grade > 2) occurred in three patients. The 1-year survival rate was 63% (median survival time, 15 months). Hepatic intraarterial injection of (90)Y-DOTA-lanreotide is a safe and effective palliative treatment for patients with progressive large-volume somatostatin receptor-positive liver metastases from neuroendocrine tumors.Keywords
This publication has 18 references indexed in Scilit:
- 111In- and 90Y-DOTA-Lanreotide: Results and implications of the MAURITIUS trialSeminars in Nuclear Medicine, 2002
- Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectivesEuropean Journal of Nuclear Medicine and Molecular Imaging, 2001
- 33. Early results of radiolabelled lanreotide in disseminated NETsNuclear Medicine Communications, 2001
- Hepatic Arterial Chemoembolization in the Management of Advanced Digestive Endocrine TumorsDigestion, 2000
- Hepatic neuroendocrine metastases: does intervention alter outcomes?1Journal of the American College of Surgeons, 2000
- Will There Be Resistance to the RECIST (Response Evaluation Criteria in Solid Tumors)?JNCI: Journal of the National Cancer Institute, 2000
- DOTA-Lanreotide: A Novel Somatostatin Analog for Tumor Diagnosis and TherapyEndocrinology, 1999
- Particle Embolization of Hepatic Neuroendocrine Metastases for Control of Pain and Hormonal SymptomsJournal of Vascular and Interventional Radiology, 1999
- Expression of Somatostatin Receptors in Normal, Inflamed, and Neoplastic Human Gastrointestinal TissuesAnnals of the New York Academy of Sciences, 1994
- Durable hepatic tumor regression after arterial chemoembolization-infusion in patients with islet cell carcinoma of the pancreas metastatic to the liverCancer, 1993